

1 The C-terminal acid phosphatase module of the RNase HI enzyme RnhC controls
2 rifampicin sensitivity and light-dependent colony pigmentation of *Mycobacterium*
3 *smegmatis*.

4 Pierre Dupuy¹ and Michael S Glickman^{1,2,†}

5 1Immunology Program, Sloan Kettering Institute, New York, NY 10065, USA.

6 2 Immunology and Microbial Pathogenesis Graduate Program, Weill Cornell Graduate School

7 [†]To whom correspondence should be addressed.

8 Immunology Program, Sloan Kettering Institute

9 1275 York Ave

10 New York, NY 10065

11 646-888-2368

12 glickmam@mskcc.org

13

14 ABSTRACT

15 RNase H enzymes participate in various processes that require processing of RNA:DNA hybrids,
16 including DNA replication, transcription, and ribonucleotide excision from DNA. Mycobacteria
17 encode multiple RNase H enzymes and prior data indicates that RNase HI activity is essential for
18 mycobacterial viability. However, the additional roles of mycobacterial RNase Hs are unknown,
19 including whether RNase HII (RnhB and RnhD) excises chromosomal ribonucleotides
20 misincorporated during DNA replication and whether individual RNase HI enzymes (RnhA and
21 RnhC) mediate additional phenotypes. We find that loss of RNase HII activity in *M. smegmatis*
22 (through combined deletion of *rnhB/rnhD*) or individual RNase HI enzymes, does not affect
23 growth, hydroxyurea sensitivity, or mutagenesis, whereas overexpression of either RNase HII
24 severely compromises bacterial viability. We also show that deletion of *rnhC*, which encodes a
25 protein with an N terminal RNase HI domain and a C terminal acid phosphatase domain, confers
26 sensitivity to rifampicin and oxidative stress as well as loss of light induced carotenoid
27 pigmentation. These phenotypes are due to loss of the activity of the C terminal acid phosphatase
28 domain rather than the RNase HI activity, suggesting that the acid phosphatase activity may
29 confer rifampicin resistance through the antioxidant properties of carotenoid pigment production.

30 INTRODUCTION

31 The basic unit of RNA, ribonucleotide triphosphates (rNTPs), are more abundant than the basic
32 unit of DNA, deoxyribonucleoside triphosphates (dNTPs), in the nucleotide pool of eukaryotic
33 and prokaryotic cells (1, 2). rNTPs differ from dNTPs by the presence of a hydroxyl group on the
34 2' carbon of the ribose, which physically clashes with a bulky residue of replicative DNA
35 polymerases, termed the steric gate, thereby limiting ribonucleotide incorporation into
36 chromosomal DNA during replication (3–5). Despite the steric gate, replicative polymerases still
37 incorporate ribonucleotides at an estimated rate of 1/1000 bases replicated (2). Genome
38 replication also incorporates ribonucleotides into DNA during lagging strand replication in the
39 form of RNA primers used for Okazaki fragments (6–8). Finally, R-loops, formed when the
40 nascent RNA anneals with the template DNA strand during transcription (9–11) is yet another
41 form of the intermingling of RNA with DNA. Cellular processing of these RNA:DNA hybrids is
42 essential for core cellular functions, including DNA replication, transcription, and repair. Failure
43 of properly process RNA:DNA hybrids induces genome instability by increasing mutations and
44 recombination (12–15).

45 To prevent deleterious effects of persistent genomic ribonucleotides, organisms encode RNase H
46 enzymes which incise the RNA strand of RNA:DNA hybrid duplexes (16–18). RNase H enzymes
47 are widely distributed in eukaryotes, prokaryotes, and retroviruses (19). They are classified into
48 two main classes: RNase HI and RNase HII (16–18). RNase HI acts on a tract of at least four
49 ribonucleotides but cannot incise a single ribonucleotide embedded in duplex DNA, whereas
50 RNase HII can incise a single embedded ribonucleotide. RNase HI enzymes are involved in the
51 degradation of R-loops and unprocessed RNA primers from Okazaki fragments, whereas RNase
52 HII initiates the ribonucleotide excision repair (RER) pathway, removing single ribonucleotides
53 from genomic DNA (16–18).

54 *Mycobacterium tuberculosis* (*Mtb*) is the human pathogen causing tuberculosis (TB). *Mtb*
55 encodes one RNase HI (RnhC/Rv2228c) and two RNase HII (RnhB/Rv2902c and
56 RnhD/Rv0776c). The non-pathogenic model organism, *Mycobacterium smegmatis*, encodes
57 RnhB, RnhC, and RnhD homologs (MSMEG 2442, MSMEG 4305, and MSMEG 5849) and an
58 additional RNase HI enzyme named RnhA (MSMEG 5562). The activities of the two
59 mycobacterial RNase HI enzymes were characterized in vitro, revealing that they incise within

60 tracts of four or more ribonucleotides in duplex DNA but not an embedded mono-ribonucleotide
61 (20–23). Interestingly, *rnhA* and *rnhC* deletions are synthetically lethal in *M. smegmatis*, showing
62 that RNase HI activity is essential in mycobacteria (21, 24). RnhB and RnhD are presumed to
63 have RNase HII activity based on sequence similarity to the *E. coli* protein. RnhD is capable of
64 hydrolyzing R-loops in vitro and in vivo and its expression complements the temperature-
65 dependent growth defect of the *E. coli* RNase H mutant (25, 26). Deletion of *M. smegmatis rnhB*
66 does not cause a growth defect, impact the level of genomic RNase HII substrates, or increase
67 genome instability (27). Finally, our previous study revealed a division of labor among all *M.*
68 *smegmatis* RNase H enzymes in tolerance to oxidative stress (21).

69 Two Mycobacterial RNase Hs, RnhC and RnhD, are bifunctional proteins. RnhD encodes, in
70 addition to the RNase HII domain, a (p)ppGpp Synthetase domain, and both modules are inactive
71 in isolation (25, 26). RnhC is composed of an N terminal RNase HI domain and an autonomous
72 C-terminal acid phosphatase domain, homologous to CobC, a α -ribazole phosphatase involved in
73 vitamin B12 biosynthesis (22, 23). Deletion of *rnhC* in *M. smegmatis* results in diminished
74 vitamin B12 levels in cells cultured in carbon limited acidic medium (28). The acid phosphatase
75 activity of RnhC does not play a role in R-loop degradation or the synthetic lethality between
76 *rnhA* and *rnhC* (21, 28).

77 Here, we investigate the relative contributions of *M. smegmatis* RNase H enzymes on growth,
78 genome stability and antibiotic sensitivity. We find that RNase HII activity is not essential for
79 optimal growth or to maintain genome stability, but overexpression of either *rnhB* or *rnhD* is
80 highly toxic for the bacterium. We show that the deletion of *rnhC*, but not other *rnh* genes,
81 increases the sensitivity of *M. smegmatis* to rifampicin. However, we demonstrate that this higher
82 rifampicin sensitivity is due to a defect in the acid phosphatase activity of RnhC, rather than its
83 RNase H activity. Finally, we show that the inactivation of the acid phosphatase activity of RnhC
84 renders *M. smegmatis* more sensitive to oxidative stress and impairs light dependent carotenoid
85 pigmentation.

86 **RESULTS**

87 **Depletion of RNase H2 does not sensitize *M. smegmatis* to hydroxyurea.**

88 Our previous data revealed that RNase HI activity (supplied by the RNase HI enzymes encoded
89 by *rnhA* and *rnhC*) is essential for mycobacterial viability (21) but RNase HII activity (supplied
90 by the proteins encoded by *rnhB* and *rnhD*) is not. However, the broader nonessential physiologic
91 roles of RNase HII enzymes in mycobacteria are not understood. Although the $\Delta rnhD$ strain had
92 a similar growth rate to WT, in-frame deletion of *rnhB* slightly impaired bacterial growth
93 (Figures 1A and B). *rnhB* is the third gene of a putative operon composed by *rplS*, *lepB* and *rnhB*.
94 Ectopic expression of *rnhB*, controlled by the *rplS* native promoter, in the $\Delta rnhB$ strain did not
95 restore WT growth rate (Figure 1C), indicating that the growth defect observed in the $\Delta rnhB$
96 mutant is not due to *rnhB* inactivation. In addition, we found that $\Delta rnhBD$, $\Delta rnhABD$, and
97 $\Delta rnhBCD$ mutants had a similar growth rate than the single $\Delta rnhB$ mutant (Figure 1B). These
98 experiments indicate that RNase HII activity is dispensable for optimal growth in *M. smegmatis*
99 in tested conditions, even in absence of one of the two RNases HI.

100 Hydroxyurea (HU) is an inhibitor of the ribonucleotide reductase enzyme that increases the
101 rNTP/dNTP ratio and may enhance misincorporation of ribonucleotides into DNA by the
102 replicative polymerase, a genomic lesion that is excised by RNase HII in many systems (29). To
103 determine whether RNase HII activity defends against HU toxicity, we measured the effect of
104 HU treatment on WT and *rnh* mutant growth. We found that HU treatment caused a similar
105 growth defect in WT, $\Delta rnhA$, and $\Delta rnhD$ strains (Figure 1D). Surprisingly, the growth defect
106 caused by HU was slightly reduced in $\Delta rnhB$ and $\Delta rnhC$ mutants (Figure 1D and E).

107 **Overexpression of *rnhB* and *rnhD* is toxic.**

108 The slightly better tolerance of the $\Delta rnhB$ and $\Delta rnhC$ strain to HU could suggest that RNase HII
109 processing of genomic ribonucleotides could be detrimental in the setting to HU treatment. To
110 test the effect of enhanced RNase HII activity, we measured the impact of RNase H
111 overexpression (OE) on growth. We constructed multi-copy plasmids with *rnhA*, *rnhB*, *rnhC*, or
112 *rnhD* under the control of the strong *groEL* promoter. Whereas we obtained many hyg^R colonies
113 after transformation with empty, *rnhA* OE, *rnhC* OE, or *rnhD* OE plasmids, no colonies were
114 obtained from the *rnhB* OE plasmid transformation (Figure S1), suggesting that high level of
115 *rnhB* expression is lethal for *M. smegmatis*.

116 To quantify the lethality of RNase H OE, we expressed *rnhA*, *rnhB*, *rnhC* or *rnhD* from an
117 Anhydrotetracycline (ATc) inducible promoter (tet promoter). In absence of inducer, the growth
118 rate of all strains was similar (Figure 2A). Addition of ATc did not impact the growth of the
119 control strain (empty vector) and OE of *rnhA* or *rnhC* caused a weak growth defect. However,
120 OE of RNase HII genes strongly impacted bacterial growth, with the strongest effect observed
121 with *rnhB* overexpression (Figure 2A). Despite minimal effect in liquid culture, growth inhibition
122 by *rnhA* OE was observed on agar medium supplemented with ATc (Figure 2B). As observed in
123 liquid culture, OE of *rnhB* and *rnhD*, but not *rnhC*, caused a strong growth defect on solid
124 medium. Together, these results show that OE of multiple RNase Hs can inhibit *M. smegmatis*
125 growth and that enhanced RNase HII activity is highly toxic.

126 **Depletion of Mycobacterial RNase HII does not affect mutation frequency.**

127 RNase HII activity is anti-mutagenic in *Bacillus subtilis* but not in *E. coli* (13, 15). To study the
128 impact of RNase H deletion on mutagenesis in mycobacteria, we measured the frequency of
129 rifampicin resistance (*rif*^R), conferred by substitution mutations in the rifampin resistance
130 determining region (RRDR) of the *rpoB* gene, in WT and *rnh* mutants. We found similar
131 spontaneous *rif*^R frequencies in WT, $\Delta rnhBD$, $\Delta rnhABD$, and $\Delta rnhBCD$ strains (figure 3A). By
132 sequencing RRDR of *rif*^R colonies, we compared the mutation spectrum of WT and *rnhBD*. In
133 WT, we detected a majority of A>G or T>C and G>A or C>T mutations with a minority of other
134 mutations (Figure 3A), and no discernable difference was observed between strains, indicating no
135 effect of the RNase H system on base substitution mutagenesis.

136 In eukaryotes, deletion of Rnase HII causes frameshift mutations (FS) due to excision of
137 embedded genomic ribonucleotides by topoisomerase (30, 31). FS mutagenesis is not detectable
138 by measuring *rif*^R frequency because RpoB is essential for viability and therefore frameshift
139 mutations would be lethal. To measure the impact of mycobacterial Rnase HII deletion on FS
140 mutagenesis, we used a reporter system, developed in a previous study (32), in which the
141 chromosomal *leuD* gene carries a 1- or 2-base pair deletion in the second codon (*leuD*⁻¹ or *leuD*⁻²),
142 conferring leucine auxotrophy. Reversion of either of these mutations by frameshifting confers
143 leucine prototrophy (*leu*⁺), which is selected on leucine free media. Using the *leuD*⁻¹ reporter,
144 similar *leu*⁺ frequencies were obtained in WT and $\Delta rnhBD$ (Figure 3B). In WT, sequencing of
145 *leuD* in *leu*⁺ revertants showed that 25% had a -1 FS in *leuD* restoring a functional open reading

146 frame, 6% had a substitution mutation generating a new in-frame start codon, 6% had $>+1$ bp
147 insertions, and the remainder had no *leuD* mutations (Figure 3B). We observed a weak induction
148 (1.5-fold) of the *leu+* frequency in the $\Delta rnhBD$ mutant using the *leuD*⁻¹ reporter (Figure 3C). In
149 WT, 25% of *leu+* had a -1 FS localized at the 3' end of the upstream *leuC* gene, generating a
150 functional in frame LeuC-LeuD fusion, 8% had a substitution mutation generating a new in-
151 frame start codon, 11% had a +1 FS in *leuD*, and 62% had no *leuC* or *leuD* mutation. The
152 $\Delta rnhBD$ mutant showed 2-fold more +1 FS in *leuD* than WT (Figure 3C). Together, these results
153 show that deletion of mycobacterial RNase HII does not affect the frequencies of spontaneous
154 substitution mutation or -1 FS frequencies and weakly enhances +1 FS events.

155 **Deletion of *rnhC* confers sensitivity to rifampicin.**

156 Our prior data indicated that loss of mycobacterial RNase H enzymes confers sensitivity to
157 oxidative damage (21). Because antibiotics are a source of oxidative stress (33, 34), we
158 investigated the impact of mycobacterial RNase H deletion on antibiotic sensitivity. We tested
159 different classes of antibiotics: rifampicin, streptomycin, ciprofloxacin, and isoniazid which
160 respectively inhibit transcription, translation, DNA replication, and cell wall synthesis. Using a
161 disc diffusion assay, we found that *rnhA* or *rnhD* deletion did not affect the *M. smegmatis*
162 sensitivity to these four antibiotics (Figures 4A, S2B, S2D, and S2E). However, the $\Delta rnhB$
163 mutant was more sensitive to rifampicin (Figure 4A), ciprofloxacin (Figure S2B), and
164 streptomycin (Figures S2A and S2D). Additional deletion of other RNase H encoding genes did
165 not exacerbate these phenotypes (Figures 4A, S2B and S2D). The higher sensitivity to
166 streptomycin was detected in two *rnhB* in-frame mutants, constructed independently, showing
167 that the phenotype is due to the *rnhB* deletion and not a random genomic mutation in another
168 gene (Figure S2A). However, ectopic expression of *rnhB* in the $\Delta rnhB$ strain did not revert the
169 mutant sensitivity to rifampicin and ciprofloxacin (Figures 4B and S2C), indicating that these
170 phenotypes are likely due to a polar effect. Intriguingly, the *rnhB* deletion induced a lower
171 sensitivity to isoniazid (Figures S2E and S2F) which was also not complemented by ectopic
172 expression of *rnhB* (Figure S2G).

173 We detected a higher sensitivity of the $\Delta rnhC$ mutant to rifampicin by disc diffusion (Figure 4A),
174 but not ciprofloxacin (Figure S2B), streptomycin (Figure S2D), or isoniazid (Figure S2E), which
175 was not exacerbated by the deletion of other RNase H enzymes. A higher sensitivity of the

176 $\Delta rnhC$ mutant to rifampicin was also detected by microplate resazurin assay (Figure S3A) as well
177 as on agar medium containing rifampicin (Figure S3B). $\Delta rnhC$ sensitivity was detected in two
178 independent *rnhC* in-frame mutants (Figure S3C) and ectopic expression of *rnhC* in the $\Delta rnhC$
179 mutant restored the WT sensitivity (Figures 4C and S3D) indicating that RnhC confers rifampicin
180 tolerance. This finding confirms recently published results using an *M. smegmatis* *rnhC* mutant
181 that was hypersensitive to Rifampin using an MIC based assay (35).

182 **Rifampicin sensitivity of the $\Delta rnhC$ mutant is not due to RNase HI activity.**

183 RnhC is a bifunctional protein composed by an N-terminal RNase HI domain and a C-terminal
184 acid phosphatase domain (22). These domains function autonomously in vitro, but the in vivo
185 substrates of the C terminal acid phosphatase domain are not known. To determine which
186 enzymatic activity of the RnhC protein is involved in rifampicin tolerance, we complemented the
187 $\Delta rnhC$ mutant with *rnhC* alleles encoding catalytic dead mutants of the RNase HI activity
188 (*rnhC*^{D73N}) or the acid phosphatase activity (*rnhC*^{H173A}) (21, 22). Ectopic expression of *rnhC*^{D73N}
189 in the $\Delta rnhC$ mutant restored rifampicin sensitivity to the same degree as wild type *rnhC* (Figure
190 5A), indicating that a defect in its RNase HI activity is not the cause of the higher sensitivity of
191 the $\Delta rnhC$ mutant. However, ectopic expression of *rnhC*^{H173A}, which does not have acid
192 phosphatase activity but retains RNase H activity (22), in the $\Delta rnhC$ strain did not restore
193 rifampicin tolerance (Figure 5A). We obtained a similar result by plating serial dilutions of these
194 strains on agar supplemented with 5 μ g/ml of rifampicin (Figure 5B). Importantly, our prior data
195 indicates that ectopic expression of the acid phosphatase defective RnhC (*rnhC*^{H173A}) in a
196 $\Delta rnhAC$ double mutant restores viability, showing that the mutated protein is expressed and that
197 the RNase HI activity is intact (21). These results reveal that RnhC acid phosphatase activity
198 protects *M. smegmatis* against rifampicin.

199 To investigate if the acid phosphatase activity of RnhC could protect bacteria against oxidative
200 stress that accompanies antibiotic treatment, we measured the sensitivity of *rnhC* mutants to
201 H₂O₂. We found that the $\Delta rnhC$ mutant was more sensitive than WT to H₂O₂ (Figure 5C).
202 Ectopic expression of *rnhC* or *rnhC*^{D73N} in $\Delta rnhC$ restored the WT sensitivity to H₂O₂, showing
203 that RnhC protects against oxidative stress, but not through its RNase HI activity (Figure 5C).
204 However, complementation of the $\Delta rnhC$ mutant by the acid phosphatase defective RnhC

205 ($rnhC^{H173A}$) did not restore rifampicin tolerance, showing that the acid phosphatase activity of
206 RnhC protects *M. smegmatis* against oxidative stress.

207 **Phosphatase activity of RnhC is involved in light-dependent pigmentation of *M. smegmatis*
208 colonies.**

209 When exposed to light, *M. smegmatis* displays weak photochromogenicity which can be observed
210 as an orange yellow pigment (36, 37). After 3 days of incubation in the dark, colonies of both WT
211 and $\Delta rnhC$ were white (Figures 6A). WT colonies became yellow when agar plates were kept
212 three days at room temperature in the light (Figures 6A, B, and C). We observed that the $\Delta rnhC$
213 mutant had a defect of yellow pigmentation after three days of light exposure (Figures 6A, B and,
214 C), a phenotype which was not visible 11 days later (Figure 6C). However, deletion of *rnhA*,
215 *rnhB* and, *rnhD*, alone or in combination, did not alter colony pigmentation (Figures 6A and C).
216 The pigmentation defect of the $\Delta rnhC$ mutant was successfully complemented by expression of
217 either WT *rnhC* or *rnhC^{D73N}*, but not by the *rnhC^{H173A}* (Figure 6B), revealing that phosphatase
218 activity, but not RNase HI activity, of RnhC is involved in light-inducible pigmentation of *M.*
219 *smegmatis*.

220 **DISCUSSION**

221 **Enigmatic biological functions of mycobacterial RNase HII.**

222 Unlike in *E. coli* and *Bacillus subtilis*, RNase HI activity is essential for the viability of *M.*
223 *smegmatis* (21, 24, 38, 39). Although biologic basis for this phenotype is still unclear, a defect in
224 processing lagging-strand RNA primers or R-loop degradation is suspected. In this study, we
225 have interrogated the roles of RNase HII activity in mycobacteria. Loss of the two *M. smegmatis*
226 RNase HII enzymes did not affect bacterial viability or mutagenesis in contrast to findings in
227 other bacteria (13, 15). However, we demonstrate that overexpression of RNase HII (either
228 encoded by *rnhB* or *rnhD*) strongly inhibits *M. smegmatis* growth.

229 The main biological function of RNase HII is excision of embedded genomic ribonucleotides
230 misincorporated by the replicative DNA polymerase (16–18). The absence of phenotype of the *M.*
231 *smegmatis* RNase HII mutant could be explained by three possibilities: 1) The genomic
232 incorporation of ribonucleotides is rare in mycobacteria or is condition specific, possibly in
233 nonreplicating states during which the rNTP:dNTP may increase; 2) Genomic ribonucleotides are
234 present but are better tolerated by mycobacteria due to more flexible DNA polymerases or more
235 efficient DNA repair pathways; 3) Alternative systems have redundant activities with
236 mycobacterial RNase HII. Minias *et al.* showed that alkaline hydrolysis of DNA is detectable at
237 similar levels in WT and $\Delta rnhB$, indicating that ribonucleotides are incorporated in mycobacterial
238 genomes (27). The extreme toxicity of RNase HII overexpression, which we postulate may be
239 due to uncontrolled genomic ribonucleotide excision, may suggest that model 2 is operative and
240 that under physiologic conditions RNase HII activity is restrained to prevent genotoxicity.
241 Further experimentation will be needed to understand the role of RNase HII in mycobacteria.

242 **RnhC protects against rifampicin through its acid phosphatase activity**

243 The RNase HI enzyme encoded by *rnhC*, while coessential with RnhA, also contains an
244 autonomous C terminal acid phosphatase domain that does not contribute to its essential function
245 (21, 22). Al-Zubaidi *et al.* recently demonstrated that the *rnhC* mutant of *M. smegmatis* led to the
246 accumulation of R-loops and a sensitivity to rifampicin (35), a finding (rif sensitivity) we
247 replicate in this study. However, our data indicates that the RNase HI activity of the RnhC
248 protein is not required for the rifampicin resistance phenotype and that the acid phosphatase
249 activity is the important biochemical activity. These data suggest that the accumulation of R-

250 loops, while clearly shown to be due to loss of *rnhC* (35) and likely due to a defect of the RNase
251 HI activity of RnhC, may not be linked to rifampicin sensitivity.

252 **RnhC controls colony pigmentation of *M. smegmatis*.**

253 In this work, we reveal that the acid phosphatase domain of RnhC is involved in light-dependent
254 yellow pigmentation of colonies in *M. smegmatis*. This pigmentation is known to be due to the
255 synthesis of carotenoids, controlled by the SigF sigma factor (36, 37). In *M. smegmatis*, as well as
256 in other orange-pigmented mycobacteria, the carotenoid molecule involved in colony
257 pigmentation is isorenieratene (36, 40–43). Isorenieratene production is catalyzed by five
258 metabolic steps in *M. smegmatis*, involving CrtE, CrtB, CrtI, CrtY, and CrtU enzymes (36). In
259 the absence of SigF, *crt* operon is not expressed and pigmentation is abolished (36, 37).

260 The mechanism by which RnhC controls *M. smegmatis* colony pigmentation is unknown. The
261 acid phosphatase domain of RnhC is homologous with the CobC α -ribazole phosphatase,
262 involved in vitamin B12 biosynthesis (22, 23). Vitamin B12 can be synthesized de novo by some
263 prokaryotes, thought complex metabolic routes, involving several dozens of enzymes (44). CobC
264 is involved in the last step of the Vitamin B12 synthesis, catalyzing dephosphorylation of
265 adenosylcobalamin-5'-phosphate (45). One possibility is that RnhC could be involved in the
266 dephosphorylation of some isorenieratene precursors, but the ultimate mechanism will require
267 further investigation.

268 **Model for the interrelationship of rifampin sensitivity, oxidative stress, and pigment
269 production**

270 We show that C-terminal acid phosphatase domain of RnhC confers tolerance to rifampicin and
271 H_2O_2 , and is required for carotenoid biosynthesis. Previous studies demonstrate that production of
272 carotenoids protects *M. smegmatis* against oxidative stress (36, 37). The bactericidal effect of
273 some antibiotics, including rifampicin, has also been linked to oxidative stress (33, 34). One
274 model to understand the higher sensitivity of the $\Delta rnhC$ mutant to rifampicin is that a failure to
275 dampen antibiotic induced oxidative stress due to the absence of carotenoids enhances the
276 potency of the antimicrobial. However, we cannot exclude the possibility that RnhC is involved
277 in the synthesis of other unidentified components protecting *M. smegmatis* from rifampicin.

278 The bifunctional RnhC protein is conserved in several mycobacteria, including pathogenic
279 species *Mtb* and *Mycobacterium leprae* (22, 23, 28). Rifampicin is a cornerstone antibiotic used
280 to treat *Mtb*. As proposed by Al-Zubaidi *et al.* (35), The higher sensitivity of the *M. smegmatis*
281 $\Delta rnhC$ mutant to rifampicin opens the possibility of targeting RnhC to potentiate rifampicin and
282 reduce the effective dose or duration of rifampicin treatment as well as attenuate the frequency of
283 resistance acquisition. However, based on our data, compounds that sensitize to rifampicin should
284 not be optimized based on the RNase HI activity but instead the acid phosphatase activity of
285 RnhC. Unlike *M. smegmatis* or *M. marinum*, *Mtb* is assumed to not synthesize carotenoids even
286 though it encodes carotenoid cleavage oxygenases (46). Therefore, the mechanisms proposed
287 here may differ in *M. tuberculosis* and future studies will be needed to assess the link between
288 RnhC, carotenoid production, and rifampicin sensitivity in *Mtb*.

289

290 **FIGURE LEGENDS**

291 **Figure 1. Depletion of RNase HII does not sensitize *M. smegmatis* to hydroxyurea. (A), (C),**

292 (D), and (E) Bacterial growth curves of indicated strains. In (C), *rnhB* is expressed ectopically

293 under its native promoter (*rpls* upstream sequence). In (E), hydroxyurea (HU) was added to

294 cultures at T0. **(B)** Doubling times of indicated strains cultivated in log phase. Results shown are

295 means (\pm SEM) of biological triplicates (A, C, D, and E) or from biological replicates

296 symbolized by grey dots (B). Stars above or under the means mark a statistical difference with

297 the reference strain (WT) (*, P<0.05; **, P<0.01; ***, P<0.001). p-values were obtained on log-

298 transformed data by two-way (A, C, D, and E) or one-way (B) ANOVA with a Bonferroni post-

299 test.

300

301 **Figure 2. Overexpression of mycobacterial RNase HII inhibits mycobacterial growth. (A)**

302 Bacterial growth curves of strains carrying an empty vector or an inducible

303 (tet=Anhydrotetracycline (ATc) inducible promoter) *rnhA*, *rnhB*, *rnhC*, or *rnhD* in absence or in

304 presence of inducer. Results shown are means (\pm SEM) of biological triplicates. Stars under the

305 means mark a statistical difference with the reference strain (empty vector) (*, P<0.05; **,

306 P<0.01; ***, P<0.001). p-values were obtained on log-transformed data by two-way ANOVA

307 with a Bonferroni post-test. **(B)** Growth of 10 fold dilutions of the indicated strains on agar

308 medium in absence or presence of inducer. Pictures are representative of experiments performed

309 in triplicate.

310 **Figure 3. Depletion of Mycobacterial RNase H does not impact substitution or frameshift**

311 **mutagenesis. (A)** Rifampicin resistance frequency (rif^R) or **(B,C)** leucine prototrophy frequency

312 (leu+) in indicated strains. Strains carry a 2-base pair (*leuD*⁻²) **(B)** or a 1-base pair (*leuD*⁻¹) **(C)**

313 deletion in the second codon of *leuD* conferring leucine auxotrophy. Results shown are means (\pm

314 SEM) of data obtained from biological replicates symbolized by grey dots. Stars above bars mark

315 a statistical difference with the reference strain (WT, *leuD*⁻¹ WT, or *leuD*⁻²) (*, P<0.05). p-values

316 were obtained on log-transformed data by one-way ANOVA with a Bonferroni post-test. Pie

317 charts shows relative frequencies of nucleotide changes (symbolized by color) detected in *rpoB*

318 of rif^r in the indicated strains (**A**) or *leuC/leuD* of leu+ in the indicated strains (**B,C**). The number
319 of sequenced rif^R or leu+ is given in the center of each pie chart.

320 **Figure 4. Loss of *rnhC* sensitizes *M. smegmatis* to rifampicin.** (**A**), (**B**), and (**C**) Sensitivities of
321 indicated strains to rifampicin measured by disc diffusion assay. In (**B**) and (**C**), *rnhB* and *rnhC*
322 are expressed ectopically under their native promoter (upstream sequences of *rplS* for *rnhB* or of
323 MSMEG_4307 for *rnhC*). Results shown are means (\pm SEM) of data obtained from biological
324 replicates symbolized by grey dots. Stars above the means mark a statistical difference with the
325 reference strain (WT (**A**), $\Delta rnhB$ (**B**), or $\Delta rnhC$ (**C**)) (*, P<0.05; **, P<0.01; ***, P<0.001). p-
326 values were obtained on log-transformed data by one-way ANOVA with a Bonferroni post-test.

327 **Figure 5. Rifampicin sensitivity of the *rnhC* mutant is due to a loss of the RnhC acid**

328 **phosphatase activity.** Sensitivities of indicated strains (*rnhC*=WT *rnhC*, *rnhC*^{D73N}=RNase HI
329 catalytic mutant of *rnhC*, *rnhC*^{H173A}=acid phosphatase catalytic mutant of *rnhC*) to (**A**) rifampicin
330 and (**C**) H₂O₂ measured by disc diffusion assay. WT or mutated versions of *rnhC* are expressed
331 ectopically under their native promoter (upstream sequence of MSMEG_4307). Results shown
332 are means (\pm SEM) of data obtained from biological replicates symbolized by grey dots. Stars
333 above the means mark a statistical difference with the reference strain ($\Delta rnhC$ +empty) (*,
334 P<0.05; **, P<0.01; ***, P<0.001). p-values were obtained on log-transformed data by one-way
335 ANOVA with a Bonferroni post-test. (**B**) Growth of indicated strains on agar medium in absence
336 or presence of rifampicin. Pictures are representative of experiments performed in triplicate.

337 **Figure 6. Acid Phosphatase activity of RnhC is involved in the light-dependent**

338 **pigmentation of *M. smegmatis*.** (**A**), (**B**) and (**C**) Colony pigmentation of indicated strains
339 (*rnhC*=WT *rnhC*, *rnhC*^{D73N}=RNase HI catalytic mutant of *rnhC*, *rnhC*^{H173A}=acid phosphatase
340 catalytic mutant of *rnhC*) cultivated on agar medium in indicated time and conditions of
341 incubation. WT or mutated versions of *rnhC* are expressed ectopically under their native
342 promoter (upstream sequence of MSMEG_4307).

343 **Methods**

344 **Bacterial strains.** Strains of this work are listed in Supplementary Table 1. *Escherichia coli* and
345 *M. smegmatis* strains were cultivated at 37°C in, respectively, Luria-Bertani (LB) medium and
346 Middlebrook 7H9 medium (Difco) supplemented with 0.5% glycerol, 0.5% dextrose, 0.1%
347 Tween 80. Streptomycin and hygromycin were respectively used at 5 µg/ml and 50 µg/ml.

348 **Plasmids and deletion mutants construct.** Plasmids of this study were constructed in *E. coli*
349 DH5 α and are listed in Supplementary Table 2. Complementation plasmids were constructing by
350 cloning ORFs together with their 5' flanking regions (~500 bp), amplified by PCR using *M.*
351 *smegmatis* mc²155 genomic DNA as template and primers listed in Supplementary Table 3, into
352 integrative pDP60 vector digested with EcoR1. *rnh* inducible and *rnh* overexpression plasmids
353 were constructed by cloning *rnhA*, *rnhB*, *rnhC*, or *rnhD* ORFs, amplified by PCR using *M.*
354 *smegmatis* mc²155 genomic DNA as template and primers listed in Supplementary Table 3, into
355 pmsg419 digested with *Cla*I and pmv261 digested with BamHI, respectively. Markerless and in-
356 frame gene deletions were performed as described in Barkan et al., 2011 using pAJF067
357 derivatives containing ~500-bp regions flanking the gene to be deleted. ORF-flanking fragments
358 were amplified by PCR using *M. smegmatis* mc²155 genomic DNA as template and primers
359 listed in Supplementary Table 3 and were cloned into pAJF067 digested with NdeI. All cloning
360 were performed using In-Fusion recombination-based cloning method (Takara) and plasmids
361 were introduced into *M. smegmatis* strains by electroporation.

362 **Growth.** 7H9 medium was inoculated with log growth phase bacteria to OD₆₀₀=0.001. Growth
363 was measured by monitoring OD₆₀₀ for two days. For *rnh*-inducible experiments, log growth
364 phase bacteria cultured without inducer (Anhydrotetracycline: ATc) were back diluted in fresh
365 7H9 medium supplemented with 50 nM of inducer to OD₆₀₀=0.001. For growth on agar medium,
366 serial dilutions of log growth phase bacteria cultivated without inducer were spotter (5 µl) on
367 7H10 medium supplemented with 50 nM of ATc and incubated at 37°C for 72 h.

368 **Disc diffusion assay.** Log growth phase bacteria were diluted in 3 ml of pre-warmed top agar
369 (7H9, 6 mg/ml agar) to an OD₆₀₀ of 0.01 and plated on 7H10. A filter disc was put on the dried
370 top agar and was spotted with 2.5 µl of 100 mg/ml rifampicin (rif), 100 mg/ml streptomycin

371 (sm), 10 mg/ml ciprofloxacin (cip), 10 mg/ml isoniazid (INH), or 10M H₂O₂. The diameter of the
372 growth inhibition zone was measured after incubation for 48 h at 37°C.

373 **Agar-based assay.** Log growth phase bacterial cultures were diluted to an OD₆₀₀ of 0.1. 5 µl of
374 serial dilutions (10⁰ to 10⁻⁵) were spotted on 7H10 or 7H10 supplemented 5-10 µg/ml rifampicin
375 or 100-200 µg/ml streptomycin. Pictures were taken after 3 days incubation at 37°C.

376 **Resazurin assay.** Log growth phase bacterial cultures were diluted to an OD₆₀₀ of 0.0005 in 7H9
377 supplemented with various concentrations of antibiotics. Cultures were incubated 2 days at 37°C
378 into 96 wells plates (100 µl of culture per plate), sealed with parafilm. 30 µl of 0.2 mg/ml
379 resazurin was added to cultures and incubated 24h at 37°C.

380 **Mutation frequency.** For measurement of substitution mutation frequency, bacteria were grown
381 to log phase in 7H9 medium from a single colony, back-diluted at an OD₆₀₀ of 0.001 in fresh
382 medium and cultured for 24 h. Cells (OD₆₀₀ ~0.5) were concentrated 40-fold by
383 centrifugation/pellet resuspension and 100 µl of a 10⁻⁶ dilution was plated on 7H10 agar whereas
384 200 µl was plated on 7H10 supplemented with 100 µg/ml rifampicin. For the measurement of FS
385 mutation frequency, cells were cultivated in 7H9 medium supplemented with 50 µg/ml leucine.
386 40-fold concentrated cultures were plated on 7H10 supplemented with 50 µg/ml leucine (100 µl
387 of a 10⁻⁶ dilution) or 7H10 (200 µl of a 10⁰ dilution). The number of independent cultures used to
388 measure the mutation frequency is indicated by the number of grey dots in each bar of graphs.
389 Mutation spectrum was established by sequencing, using primers listed in Supplementary Table
390 3, the rifampicin resistance determining region (RRDR) of the *rpoB* gene of isolated rif^R colonies
391 or *leuCD* genes of isolated leu⁺ colonies, amplified by PCR. For each strain, sequenced colonies
392 were picked among at least six biological replicates.

393 **Colony pigmentation assay.** Log phase bacteria cultivated in 7H9 were plated (serial dilution
394 spotting or streaking of an undiluted culture) on 7H10 and incubated in dark at 37°C for 3 days.
395 Plates were kept at room temperature for 3 days or more under natural light.

396 **Data availability**

397 Further information and requests for resources and reagents should be directed to and will be
398 fulfilled by Dr. Michael Glickman (Glickmam@mskcc.org). Plasmids and strains generated in
399 this study will be made available on request. All data generated in this study are presented in the
400 Figures and Tables. Any additional information required to reanalyze the data reported in this
401 paper is available from the lead contact upon request.

402 **Acknowledgments**

403 This work is supported by NIH (NIH grant #AI064693) and this research was funded in part
404 through the NIH/NCI Cancer Center Support Grant P30CA008748. P. Dupuy was supported in
405 part by a « Jeune Scientifique » salary award from the French National Institute of Agronomic
406 Science (INRA). We thank all Glickman lab members for helpful discussions.

407 **Author contributions**

408 P.D. and M.G. designed research; P.D. performed research; P.D. and M.G. analyzed data; P.D.
409 and M.G. wrote the paper.

410 **Competing interests**

411 MG has received consulting fees from Vedanta Biosciences, PRL NYC, and Fimbrion
412 Therapeutics and has equity in Vedanta biosciences.

413 **Supplementary data**

414 Supplementary Figures S1-S3 and Supplementary Tables S1-S3.

415 **References**

- 416 1. Traut TW. 1994. Physiological concentrations of purines and pyrimidines. *Mol Cell*
417 *Biochem* 140:1–22.
- 418 2. Nick McElhinny SA, Watts BE, Kumar D, Watt DL, Lundström E-B, Burgers PMJ,
419 Johansson E, Chabes A, Kunkel TA. 2010. Abundant ribonucleotide incorporation into
420 DNA by yeast replicative polymerases. *Proc Natl Acad Sci U S A* 107:4949–4954.
- 421 3. DeLucia AM, Grindley NDF, Joyce CM. 2003. An error-prone family Y DNA polymerase
422 (DinB homolog from *Sulfolobus solfataricus*) uses a “steric gate” residue for discrimination
423 against ribonucleotides. *Nucleic Acids Res* 31:4129–4137.
- 424 4. Ordonez H, Uson ML, Shuman S. 2014. Characterization of three mycobacterial DinB
425 (DNA polymerase IV) paralogs highlights DinB2 as naturally adept at ribonucleotide
426 incorporation. *Nucleic Acids Res* 42:11056–11070.
- 427 5. Joyce CM. 1997. Choosing the right sugar: how polymerases select a nucleotide substrate.
428 *Proc Natl Acad Sci U S A* 94:1619–1622.
- 429 6. Rowen L, Kornberg A. 1978. A ribo-deoxyribonucleotide primer synthesized by primase. *J*
430 *Biol Chem* 253:770–774.
- 431 7. Rowen L, Kornberg A. 1978. Primase, the dnaG protein of *Escherichia coli*. An enzyme
432 which starts DNA chains. *J Biol Chem* 253:758–764.
- 433 8. Balakrishnan L, Bambara RA. 2013. Okazaki fragment metabolism. *Cold Spring Harb*
434 *Perspect Biol* 5:a010173.
- 435 9. Thomas M, White RL, Davis RW. 1976. Hybridization of RNA to double-stranded DNA:
436 formation of R-loops. *Proc Natl Acad Sci U S A* 73:2294–2298.
- 437 10. Aguilera A, García-Muse T. 2012. R Loops: From Transcription Byproducts to Threats to
438 Genome Stability. *Mol Cell* 46:115–124.
- 439 11. García-Muse T, Aguilera A. 2019. R Loops: From Physiological to Pathological Roles. *Cell*
440 179:604–618.
- 441 12. Klein HL. 2017. Genome Instabilities Arising from Ribonucleotides in DNA. *DNA Repair*
442 56:26–32.
- 443 13. Schroeder JW, Randall JR, Hirst WG, O'Donnell ME, Simmons LA. 2017. Mutagenic cost
444 of ribonucleotides in bacterial DNA. *Proc Natl Acad Sci* 114:11733–11738.
- 445 14. Williams JS, Kunkel TA. 2014. Ribonucleotides in DNA: Origins, repair and consequences.
446 *DNA Repair* 19:27–37.
- 447 15. Yao NY, Schroeder JW, Yurieva O, Simmons LA, O'Donnell ME. 2013. Cost of
448 rNTP/dNTP pool imbalance at the replication fork. *Proc Natl Acad Sci* 110:12942–12947.

449 16. Tadokoro T, Kanaya S. 2009. Ribonuclease H: molecular diversities, substrate binding
450 domains, and catalytic mechanism of the prokaryotic enzymes. *FEBS J* 276:1482–1493.

451 17. Cerritelli SM, Crouch RJ. 2009. Ribonuclease H: the enzymes in eukaryotes. *FEBS J*
452 276:1494–1505.

453 18. Hyjek M, Figiel M, Nowotny M. 2019. RNases H: Structure and mechanism. *DNA Repair*
454 84:102672.

455 19. Ohtani N, Haruki M, Morikawa M, Kanaya S. 1999. Molecular diversities of RNases H. *J*
456 *Biosci Bioeng* 88:12–19.

457 20. Dawes SS, Crouch RJ, Morris SL, Mizrahi V. 1995. Cloning, sequence analysis,
458 overproduction in *Escherichia coli* and enzymatic characterization of the RNase HI from
459 *Mycobacterium smegmatis*. *Gene* 165:71–75.

460 21. Gupta R, Chatterjee D, Glickman MS, Shuman S. 2017. Division of labor among
461 *Mycobacterium smegmatis* RNase H enzymes: RNase H1 activity of RnhA or RnhC is
462 essential for growth whereas RnhB and RnhA guard against killing by hydrogen peroxide in
463 stationary phase. *Nucleic Acids Res* 45:1–14.

464 22. Jacewicz A, Shuman S. 2015. Biochemical Characterization of *Mycobacterium smegmatis*
465 RnhC (MSMEG_4305), a Bifunctional Enzyme Composed of Autonomous N-Terminal
466 Type I RNase H and C-Terminal Acid Phosphatase Domains. *J Bacteriol* 197:2489–2498.

467 23. Watkins HA, Baker EN. 2010. Structural and functional characterization of an RNase HI
468 domain from the bifunctional protein Rv2228c from *Mycobacterium tuberculosis*. *J*
469 *Bacteriol* 192:2878–2886.

470 24. Minias AE, Brzostek AM, Machala MK-, Dziadek B, Minias P, Rajagopalan M, Madiraju
471 M, Dziadek J. 2015. RNase HI Is Essential for Survival of *Mycobacterium smegmatis*.
472 *PLOS ONE* 10:e0126260.

473 25. Krishnan S, Petchiappan A, Singh A, Bhatt A, Chatterji D. 2016. R-loop induced stress
474 response by second (p)ppGpp synthetase in *Mycobacterium smegmatis*: functional and
475 domain interdependence. *Mol Microbiol* 102:168–182.

476 26. Murdeshwar MS, Chatterji D. 2012. MS_RHII-RSD, a dual-function RNase HII-(p)ppGpp
477 synthetase from *Mycobacterium smegmatis*. *J Bacteriol* 194:4003–4014.

478 27. Minias AE, Brzostek AM, Minias P, Dziadek J. 2015. The Deletion of rnhB in
479 *Mycobacterium smegmatis* Does Not Affect the Level of RNase HII Substrates or Influence
480 Genome Stability. *PLOS ONE* 10:e0115521.

481 28. Czubat B, Minias A, Brzostek A, Żaczek A, Struś K, Zakrzewska-Czerwińska J, Dziadek J.
482 2020. Functional Disassociation Between the Protein Domains of MSMEG_4305 of
483 *Mycolicibacterium smegmatis* (*Mycobacterium smegmatis*) in vivo. *Front Microbiol*
484 11:2008.

485 29. Williams JS, Kunkel TA. 2014. Ribonucleotides in DNA: Origins, repair and consequences.
486 DNA Repair 19:27–37.

487 30. Kim N, Huang SN, Williams JS, Li YC, Clark AB, Cho J-E, Kunkel TA, Pommier Y, Jinks-
488 Robertson S. 2011. Mutagenic processing of ribonucleotides in DNA by yeast
489 topoisomerase I. Science 332:1561–1564.

490 31. Sekiguchi J, Shuman S. 1997. Site-Specific Ribonuclease Activity of Eukaryotic DNA
491 Topoisomerase I. Mol Cell 1:89–97.

492 32. Dupuy Pi, Ghosh S, Adefisayo OO, Buglino J, Shuman S, Glickman MS. 2022. Distinctive
493 roles of translesion polymerases DinB1 and DnaE2 in diversification of the mycobacterial
494 genome through substitution and frameshift mutagenesis. bioRxiv
495 <https://doi.org/10.1101/2022.03.06.483125>.

496 33. Dupuy P, Howlader M, Glickman MS. 2020. A multilayered repair system protects the
497 mycobacterial chromosome from endogenous and antibiotic-induced oxidative damage.
498 Proc Natl Acad Sci 117:19517–19527.

499 34. Foti JJ, Devadoss B, Winkler JA, Collins JJ, Walker GC. 2012. Oxidation of the guanine
500 nucleotide pool underlies cell death by bactericidal antibiotics. Science 336:315–319.

501 35. Al-Zubaidi A, Cheung C-Y, Cook GM, Taiaroa G, Mizrahi V, Lott JS, Dawes SS. 2022.
502 RNase HI Depletion Strongly Potentiates Cell Killing by Rifampicin in Mycobacteria.
503 Antimicrob Agents Chemother 66:e0209121.

504 36. Provvedi R, Kocíncová D, Donà V, Euphrasie D, Daffé M, Etienne G, Manganelli R, Reyrat
505 J-M. 2008. SigF Controls Carotenoid Pigment Production and Affects Transformation
506 Efficiency and Hydrogen Peroxide Sensitivity in *Mycobacterium smegmatis*. J Bacteriol
507 190:7859–7863.

508 37. Singh AK, Dutta D, Singh V, Srivastava V, Biswas RK, Singh BN. 2015. Characterization
509 of *Mycobacterium smegmatis* sigF mutant and its regulon: overexpression of SigF
510 antagonist (MSMEG_1803) in *M. smegmatis* mimics sigF mutant phenotype, loss of
511 pigmentation, and sensitivity to oxidative stress. MicrobiologyOpen 4:896–916.

512 38. Fukushima S, Itaya M, Kato H, Ogasawara N, Yoshikawa H. 2007. Reassessment of the in
513 vivo functions of DNA polymerase I and RNase H in bacterial cell growth. J Bacteriol
514 189:8575–8583.

515 39. Itaya M, Omori A, Kanaya S, Crouch RJ, Tanaka T, Kondo K. 1999. Isolation of RNase H
516 genes that are essential for growth of *Bacillus subtilis* 168. J Bacteriol 181:2118–2123.

517 40. Britton G, Goodwin TW, Brown DJ, Patel NJ. 1980. Carotenoid biosynthesis by cultures
518 and cell-free preparations of *Flavobacterium R1560*. Methods Enzymol 67:264–270.

519 41. Goodwin TW, Jamikorn M. 1956. Studies in carotenogenesis. 17. The carotenoids produced
520 by different strains of *Mycobacterium phlei*. Biochem J 62:269–275.

521 42. Levy-Frebault V, David HL. 1979. Mutations affecting pigment synthesis in
522 *Mycobacterium aurum*. *J Gen Microbiol* 115:317–323.

523 43. Tárnok I, Tárnok Z. 1970. Carotene and xanthophylls in mycobacteria. I. Technical
524 procedures; thin-layer chromatographic patterns of mycobacterial pigments. *Tubercle*
525 51:305–312.

526 44. Fang H, Kang J, Zhang D. 2017. Microbial production of vitamin B12: a review and future
527 perspectives. *Microb Cell Factories* 16:15.

528 45. Zayas CL, Escalante-Semerena JC. 2007. Reassessment of the late steps of coenzyme B12
529 synthesis in *Salmonella enterica*: evidence that dephosphorylation of adenosylcobalamin-5'-
530 phosphate by the CobC phosphatase is the last step of the pathway. *J Bacteriol* 189:2210–
531 2218.

532 46. Scherzinger D, Scheffer E, Bär C, Ernst H, Al-Babili S. 2010. The *Mycobacterium*
533 tuberculosis ORF Rv0654 encodes a carotenoid oxygenase mediating central and excentric
534 cleavage of conventional and aromatic carotenoids. *FEBS J* 277:4662–4673.

535 47. Barkan D, Stallings CL, Glickman MS. 2011. An improved counterselectable marker
536 system for mycobacterial recombination using *galK* and 2-deoxy-galactose. *Gene* 470:31–
537 36.

538




Figure 1. Depletion of RNase HII does not sensitize *M. smegmatis* to hydroxyurea. (A), (C), (D), and (E) Bacterial growth curves of indicated strains. In (C), *rnhB* is expressed ectopically under its native promoter (*rplS* upstream sequence). In (E), hydroxyurea (HU) was added to cultures at T0. (B) Doubling times of indicated strains cultivated in log phase. Results shown are means (\pm SEM) of biological triplicates (A, C, D, and E) or from biological replicates symbolized by grey dots (B). Stars above or under the means mark a statistical difference with the reference strain (WT) (*, $P<0.05$; **, $P<0.01$; ***, $P<0.001$). p -values were obtained on log-transformed data by two-way (A, C, D, and E) or one-way (B) ANOVA with a Bonferroni post-test.




Figure 2. Overexpression of mycobacterial RNase HII inhibits mycobacterial growth. (A) Bacterial growth curves of strains carrying an empty vector or an inducible (tet=Anhydrotetracycline (ATc) inducible promoter) *rnhA*, *rnhB*, *rnhC*, or *rnhD* in absence or in presence of inducer. Results shown are means (\pm SEM) of biological triplicates. Stars under the means mark a statistical difference with the reference strain (empty vector) (*, $P<0.05$; **, $P<0.01$; ***, $P<0.001$). P -values were obtained on log-transformed data by two-way ANOVA with a Bonferroni post-test. (B) Growth of 10 fold dilutions of the indicated strains on agar medium in absence or presence of inducer. Pictures are representative of experiments performed in triplicate.




Figure 3. Depletion of Mycobacterial RNase H does not impact substitution or frameshift mutagenesis. (A) Rifampicin resistance frequency (rif^R) or (B,C) leucine prototrophy frequency (Leu^+) in indicated strains. Strains carry a 2-base pair (leuD^2) (B) or a 1-base pair (leuD^1) (C) deletion in the second codon of leuD conferring leucine auxotrophy. Results shown are means (\pm SEM) of data obtained from biological replicates symbolized by grey dots. Stars above bars mark a statistical difference with the reference strain (WT, leuD^1 WT, or leuD^2) (*, $P<0.05$). p -values were obtained on log-transformed data by one-way ANOVA with a Bonferroni post-test. Pie charts shows relative frequencies of nucleotide changes (symbolized by color) detected in rpoB of rif^R in the indicated strains (A) or leuC/leuD of Leu^+ in the indicated strains (B,C). The number of sequenced rif^R or Leu^+ is given in the center of each pie chart.




Figure 4. Loss of *rnhC* sensitizes *M. smegmatis* to rifampicin. (A), (B), and (C) Sensitivities of indicated strains to rifampicin measured by disc diffusion assay. In (B) and (C), *rnhB* and *rnhC* are expressed ectopically under their native promoter (upstream sequences of *rplS* for *rnhB* or of MSMEG_4307 for *rnhC*). Results shown are means (\pm SEM) of data obtained from biological replicates symbolized by grey dots. Stars above the means mark a statistical difference with the reference strain (WT (A), $\Delta rnhB$ (B), or $\Delta rnhC$ (C)) (*, P<0.05; **, P<0.01; ***, P<0.001). p-values were obtained on log-transformed data by one-way ANOVA with a Bonferroni post-test.




Figure 5. Rifampicin sensitivity of the *rnhC* mutant is due to a loss of the RnhC acid phosphatase activity. Sensitivities of indicated strains (*rnhC*=WT *rnhC*, *rnhC*^{D73N}=RNase HI catalytic mutant of *rnhC*, *rnhC*^{H173A}=acid phosphatase catalytic mutant of *rnhC*) to (A) rifampicin and (C) H₂O₂ measured by disc diffusion assay. WT or mutated versions of *rnhC* are expressed ectopically under their native promoter (upstream sequence of MSMEG_4307). Results shown are means (± SEM) of data obtained from biological replicates symbolized by grey dots. Stars above the means mark a statistical difference with the reference strain (Δ*rnhC*+empty) (*, P<0.05; **, P<0.01; ***, P<0.001). p-values were obtained on log-transformed data by one-way ANOVA with a Bonferroni post-test. (B) Growth of indicated strains on agar medium in absence or presence of rifampicin. Pictures are representative of experiments performed in triplicate.




Figure 6. Acid Phosphatase activity of RnhC is involved in the light-dependent pigmentation of *M. smegmatis*. (A), (B) and (C) Colony pigmentation of indicated strains (*rnhC*=WT *rnhC*, *rnhC*^{D73N}=RNase HI catalytic mutant of *rnhC*, *rnhC*^{H173A}=acid phosphatase catalytic mutant of *rnhC*) cultivated on agar medium in indicated time and conditions of incubation. WT or mutated versions of *rnhC* are expressed ectopically under their native promoter (upstream sequence of MSMEG_4307).